Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771533 | 0.86 | MAPT (0.46) | CNR2CYP4F2CYP4A11CTSBCTSS | |
| SCHEMBL4771518 | 0.85 | SPHK1 (0.37) | CNR2CTSBCTSSCTSLGLS | |
| SCHEMBL7839161 | 0.84 | MAPT (0.42) | CNR2CYP4F2CYP4A11CTSBCTSS | |
| SCHEMBL5101551 | 0.81 | NPSR1 (0.43) | CNR2CYP4F2CYP4A11CTSBCTSS | |
| SCHEMBL5138860 | 0.79 | CYP4F2 (0.36) | CNR2CYP4F2CYP4A11CTSBCTSS | |
| SCHEMBL500447 | 0.77 | SPHK1 (0.49) | CNR2CYP4F2CYP4A11CTSBCTSS | |
| SCHEMBL10550076 | 0.77 | CYP4F2 (0.37) | CYP4F2CYP4A11CTSBCTSSCTSL | |
| SCHEMBL9671904 | 0.76 | SPHK1 (0.48) | CNR2CYP4F2CYP4A11CTSBCTSS | |
| SCHEMBL13502694 | 0.76 | CTSB (0.36) | CNR2CYP4F2CYP4A11CTSBCTSS | |
| SCHEMBL8485391 | 0.76 | CNR2 (0.39) | CNR2CYP4F2CYP4A11CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2002837-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1094816-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6852745-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-6835741-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | CNR2 105/4885CYP4F2 2018/4885CYP4A11 447/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | CNR2 105/4885CYP4F2 2018/4885CYP4A11 447/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | CNR2 105/4885CYP4F2 2018/4885CYP4A11 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.